

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[← Back](#)

[Tangible Materials Available for Licensing](#)

[Main Publications & Treatment](#)

[Refer a Patient](#)

## ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

inhibitor) and cetuximab (a monoclonal antibody that blocks ligand binding to EGFR and prevents downstream signaling), two commonly used drugs targeting ErbB receptors. These cells are capable of forming tumors in immunocompromised mice.

## Source

This cell line was established in 1975 from a metastatic site (pleural effusion) in a 25-year-old Caucasian male with adenocarcinoma of the lung.

## Inventors

Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

## Key References

Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. *Journal of the National Cancer Institute* 59: 221-226 (PubMed ID: [327080](#))

Cavazzoni A et al. (2012) Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. *Molecular Cancer* 11: 91 (PubMed ID: [23234355](#))

Blanco R et al. (2009) A gene-alteration profile of human lung cancer cell lines. *Human Mutation* 30: 1199–1206 (PubMed ID: [19472407](#))

# Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Express License: For internal research purposes by a for-profit entity: Fill out MSK’s Core Express License; see [here](#) for links to the online fillable Core Express License, as well as a PDF version. For detailed guidance on how to fill out this webform, see [here](#). Please note: In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. This license is only available for select cell lines, including this one. Once this license has been executed by MSK, you will receive a signed copy and payment instructions; all payments up to \$10,000 must be made by credit card.

Commercial License: Contact MSK’s Tangible Research Materials team at [TRMOTDRTM@mskcc.org](mailto:TRMOTDRTM@mskcc.org).

For non-licensing requests from academic-research institutions : Contact MSK’s Antibody & Bioresource Core Facility at [skiabcf@mskcc.org](mailto:skiabcf@mskcc.org).

## Stage of Development

Ready to use

## Indications

[Cancer](#) > [Lung](#)

## Types

[Research Tools](#) > [Cell Lines](#)



[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

## ▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

---

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center